Pfizer will earn $15 billion from sales of its Coronavirus vaccine developed in collaboration with BioNTech.
The American pharmaceutical company forecasts $59.4 billion and $61.4 billion revenue in 2021 and expects a quarter of its total revenue this year to come from the sales of its COVID-19 vaccine.
ALSO READ
Here is How Govt. Plans to Vaccinate All Citizens Before The End of 2021
During an interview, CEO Pfizer, Albert Bourla, said that the company is on track to produce 2 billion doses of Coronavirus vaccines this year which will see it earn $15 billion.
We’ve increased the batches we run per week, we’ve doubled the output – the yield per batch – we’ve dramatically improved our success rates, we’ve made process improvements to the assembly lines.
ALSO READ
Govt. to Store Coronavirus Vaccine Doses at High-Security Facilities
Albert Bourla added that Pfizer could exceed the $15 billion mark if the company signs more supply contracts.
Besides, Pfizer has launched a study to determine whether a third dose of its mRNA-based Coronavirus vaccine, administered 6-12 months after the first two doses which are injected three weeks apart, can increase the immunity against the more infectious variants of Coronavirus reported across the world.
